Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accredited, accretion, Administratiekantoor, aficamten, Agricultural, aimed, Amaury, begun, beta, Bristol, BSc, built, calcium, called, cardiac, cardiology, cardiomyopathy, channel, Charter, cited, CKD, Clawback, CME, conjunction, decoy, deploy, deployed, diane, DPNP, earliest, email, enterprise, exert, filtering, focused, foundational, France, Garner, HCM, honeypot, hypertrophic, INPEFA, INSEAD, intelligence, intent, intrusion, KCCQ, left, mavacamten, multidisciplinary, myosin, NOOH, obesity, obstructive, oral, Overnight, path, pause, prepaid, pro, promptly, prospectively, pushing, Questionnaire, rata, reclassification, refinance, regular, resale, resell, resubmit, routine, Royal, screening, Secretary, SGLT, SOFR, Stichting, sullivan, sum, symptom, tablet, tabletop, threat, tool, unused, url, ventricular, visit, warehousing, Westend, wholesaler, Wittouck
Removed:
acquire, acute, administered, Aid, annum, antibody, applying, approximate, assigned, balloon, Bank, bifurcation, billed, BioPharma, biotherapeutic, bone, BVF, capitalization, CGM, chargeback, circumstance, close, compare, comparing, consisted, conversion, COSO, deducted, depletion, detail, diarrhea, discussed, distributor, DPN, economy, eGFR, emergency, encounter, extinguishment, Fargo, fifty, filtration, formed, frank, fulfillment, Genentech, genital, glomerular, hemoglobin, HFpEF, HFrEF, hospital, hospitalized, Houston, hypotension, Icon, ii, indenture, indirect, infarction, infrequent, inside, intangible, Ipsen, largest, led, licensed, LP, MACE, match, measuring, median, merger, minute, ml, mortgage, multiplied, mycotic, myocardial, negotiated, nonclinical, occurring, optimal, originally, palantoni, parallel, participant, percent, pertain, plant, pooled, preserved, prespecified, privately, recurrent, refinancing, region, relief, renamed, repayment, residual, retailer, scheduled, SCORED, secreted, sector, semiannually, SOLOIST, specification, spend, step, stroke, subset, surface, Symphony, territory, TerSera, thereon, tract, traded, transfer, translate, trustee, unqualified, urinary, wholly, worsening, XERMELO
Financial report summary
?Competition
Astrazeneca • Cytokinetics • Novartis • Reata Pharmaceuticals • Jaguar Health • Advanced Accelerator Applications • Crinetics PharmaceuticalsManagement Discussion
- •Third-party services – Third-party services relate principally to our clinical trial and related development activities, such as preclinical and clinical studies and contract manufacturing. Overall, third-party services increased 16% in 2023 to $34.6 million, primarily related to increased manufacturing and external research and development costs. These costs were partially offset by lower professional and consulting fees in 2023 when compared to costs incurred in 2022 related to preparations for the submission of our application for regulatory approval to market INPEFA for heart failure in the United States.
- •Personnel – Personnel costs increased 6% in 2023 to $14.3 million from $13.5 million in 2022, due to increased headcount in 2023. Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.
- •Stock-based compensation – Stock-based compensation expense increased 21% in 2023 to $5.1 million as compared to 2022, partially due to increased headcount.